Table 1.
Covariate | PGD (n = 30) | Non-PGD (n = 87) | P Value |
---|---|---|---|
Donor characteristics | |||
Smoke exposure, n (%) | 7 (28.0) (n = 25) | 12 (16.0) (n = 75) | 0.19 |
Cause of death, n (%) | n = 27 | n = 75 | 0.06 |
Head trauma | 12 (44.4) | 27 (36.0) | |
Anoxia | 0 (0.0) | 16 (21.3) | |
Stroke | 12 (44.4) | 28 (37.3) | |
Other | 3 (11.1) | 4 (5.3) | |
Recipient characteristics | |||
Age, yr | 58.0 [52.2–60.5] | 56.5 [49.5–60.5] | 0.60 |
Male sex, n (%) | 20 (66.7) | 56 (64.4) | 0.82 |
Race/ethnicity, n (%) | 0.14 | ||
Caucasian | 22 (73.3) | 75 (86.2) | |
African American | 7 (23.3) | 8 (9.2) | |
Other | 1 (3.3) | 4 (4.6) | |
Body mass index, kg/m2 | 29.7 ± 5.0 | 26.6 ± 4.9 | 0.004 |
History of hypertension, n (%) | 15 (50.0) | 26 (29.9) | 0.05 |
Use of antihypertensive or diuretic, n (%) | 19 (63.3) | 30 (34.5) | 0.006 |
History of diabetes, n (%) | 6 (20.0) | 12 (13.8) | 0.42 |
History of coronary artery disease, n (%) | 11 (36.7) | 32 (36.8) | 0.99 |
History of obstructive sleep apnea, n (%) | 4 (13.3) | 9 (10.3) | 0.65 |
Supplemental O2 with exertion, L | 10 [6–100] | 5.5 [3–10] (n = 86) | 0.009 |
Six-minute walk distance, ft | 965.8 ± 278.8 | 1046.4 ± 351.3 (n = 86) | 0.26 |
Pretransplant diagnosis, n (%) | 0.001 | ||
Chronic obstructive pulmonary disease | 6 (20.0) | 49 (56.3) | |
Interstitial lung disease | 19 (63.3) | 35 (40.2) | |
Pulmonary arterial hypertension | 5 (16.7) | 3 (3.5) | |
Pulmonary function tests | |||
FVC, % predicted | 49 [40–73] | 51 [42–63] (n = 86) | 0.83 |
FEV1, % predicted | 46.5 [31–63] | 29.5 [17–50] (n = 86) | 0.003 |
FEV1/FVC | 84 [56–86] | 38 [26–85] | 0.02 |
TLC, % predicted | 75 [54–110] (n = 26) | 100 [58–125] (n = 69) | 0.10 |
DlCO, % predicted | 30.5 [21–38.5] (n = 16) | 34 [27–47] (n = 49) | 0.18 |
Definition of abbreviations: DlCO = diffusing capacity of the lung for carbon monoxide; PGD = primary graft dysfunction; TLC = total lung capacity.
Data are given as mean ± SD, median [interquartile range], or n (%).